<?xml version="1.0" encoding="UTF-8"?>
<xml>
 <records>
  <record>
   <ref-type name="Journal Article">17</ref-type>
   <contributors>
    <authors>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author>Хамитова А. Ф.</author>
     <author>Лакман И. А.</author>
     <author>Ахметвалеев Р. Р.</author>
     <author>Тулбаев Э. Л.</author>
     <author>Гареева Д. Ф.</author>
     <author>Загидуллин Ш. З.,</author>
     <author>Загидуллин Н. Ш.</author>
    </authors>
   </contributors>
   <titles>
    <title>Многофакторная прогностическая модель у пациентов с инфарктом миокарда в отдаленном периоде на основе современных биомаркеров</title>
   </titles>
   <dates>
    <year>2020</year>
    <pub-dates>
     <date>2020-11-12</date>
    </pub-dates>
   </dates>
   <doi>10.18087/cardio.2020.3.2593</doi>
   <abstract>Objective To study the prognostic role of current serum biomarkers in patients with myocardial infarction (MI) by constructing a multifactorial model for prediction of cardiovascular complications (CVC) in remote MI. Acute coronary syndrome is a major cause of death and disability in the Russian Federation. Introduction of current biomarkers, such as N-terminal pro-brain natriuretic peptide, stimulating growth factor (ST2), and centraxin-2 (Pentraxin, Ptx-3), provides more possibilities for diagnostics and calculation of risk for CVC.Materials and Methods Concentrations of biomarkers were measured in 180 patients with MI (mean age, 61.4±1.7) upon admission. At one year, specific and composite endpoints were determined (MI, acute cerebrovascular disease, admission for CVD, and cardiovascular death). Based on this information, a prognostic model for subsequent events was developed.Results A mathematical model was created for computing the development of a composite endpoint. In this model, the biomarkers NT-proBNP, Ptx-3 and, to a lesser extent, ST2 demonstrated their prognostic significance in diagnosis of CVC with a sensitivity of 78.79 % and specificity of 86.67 % (area under the curve, AUC 0.73).Conclusion In patients with remote MI, the biomarkers NT-proBNP, ST2, and Ptx-3 improve prediction of CVC.</abstract>
   <urls>
    <web-urls>
     <url>https://repo.bashgmu.ru/publication/848</url>
    </web-urls>
    <pdf-urls>
     <url>https://repo.bashgmu.ru/files/971</url>
    </pdf-urls>
   </urls>
  </record>
 </records>
</xml>
